Deeply Experienced Brand Marketer to Help Increase Awareness of CMT and Accelerate Research
ATLANTA (September 21, 2020) The CMT Research Foundation, a nonprofit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease during our lifetime, today announced that Susan B. Canavari, a senior executive with more than 30 years of brand marketing experience, has joined its Board of Directors. This expands the board to eight members who oversee the Foundation’s fundraising and research operations.
“Susan is immensely talented and energetic,” says Patrick Livney, co-founder and chairman of the CMT Research Foundation Board of Directors. “We are pleased to welcome her and can’t wait to implement her ideas and strategies to build greater awareness of our vital work to find cures for this tragic disease.”
Charcot-Marie-Tooth is a progressive nerve disease that causes the muscles in the hands, arms, legs and feet to weaken and deteriorate, making everyday activities like walking, running, maintaining balance and using one’s hands a challenge. CMT affects one in 2,500 people (more than have ALS or cystic fibrosis), including 150,000 Americans and nearly three million people worldwide.
Ms. Canavari is the senior vice president of marketing for TIAA, a New York City-based Fortune 100 financial services organization that provides financial services to the academic, research, medical, cultural and governmental fields. Before her time at TIAA, she was the global chief brand and experience officer for JPM Wealth Management where she was responsible for brand and experience for JPM’s Asset Management and Private Bank Businesses. She started at JPM Chase as the chief brand officer for Chase where she worked on marketing all lines of business, including cards, retail bank and Chase for Business as well as ran the internal creative services, newsroom and global employee recruitment marketing.
Earlier in her career, Ms. Canavari worked at several top advertising agencies; she was a managing director of Mcgarrybowen, a global, full-service, integrated marketing communications agency network; and held senior positions at Digitas and Ogilvy & Mather. She holds a B.S. in Mass Communication from Miami (Ohio) University and an M.B.A. from Boston College.
“I have friends whose relatives are suffering from CMT, and I look forward to helping find treatments and cures through the CMT Research Foundation’s vital work,” says Ms. Canavari. “I’m honored to join such a talented board of directors with excellence in both management and scientific expertise.”
The CMT Research Foundation is a nonprofit dedicated to delivering treatments and cures for CMT during our lifetime. We invest in research exclusively focused on drug development, pursue creative and unconventional strategies to advance scientific discovery, and partner with leading experts and patients to speed urgently needed answers to families. Learn more and join us to end CMT at cmtrf.org.
